ReP USP - Resultado da busca

Artigo de periodico
Systemic solutions for addressing non-communicable diseases in low- and middle-income countries (2020)
Ganju, Aakash; Goulart, Alessandra Carvalho ; Ray, Amrit; Majumdar, Anurita; Jeffers, Barrett W; Llamosa, Gloria; Cañizares, Henry; Ramos-Cañizares, Ianne Jireh; Fadhil, Ibtihal; Subramaniam, Kannan; Lim, Lee-Ling; El Bizri, Luna; Ramesh, M; Guilford, Mathew; Ali, Raghib; Devi, Ratna Duddi; Malik, Rayaz A; Potkar, Shekhar; Wang, Yuan-Pang
Fonte: Journal of Multidisciplinary Healthcare. Unidade: HU
Assuntos: CONTROLE DE DOENÇAS NÃO TRANSMISSÍVEIS, SISTEMA DE SAÚDE, PARCERIA PÚBLICO-PRIVADA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GANJU, Aakash et al. Systemic solutions for addressing non-communicable diseases in low- and middle-income countries. Journal of Multidisciplinary Healthcare, v. 13, p. 693-707, 2020Tradução . . Disponível em: https://doi.org/10.2147/JMDH.S252300. Acesso em: 15 nov. 2024.
APA
Ganju, A., Goulart, A. C., Ray, A., Majumdar, A., Jeffers, B. W., Llamosa, G., et al. (2020). Systemic solutions for addressing non-communicable diseases in low- and middle-income countries. Journal of Multidisciplinary Healthcare, 13, 693-707. doi:10.2147/JMDH.S252300
NLM
Ganju A, Goulart AC, Ray A, Majumdar A, Jeffers BW, Llamosa G, Cañizares H, Ramos-Cañizares IJ, Fadhil I, Subramaniam K, Lim L-L, El Bizri L, Ramesh M, Guilford M, Ali R, Devi RD, Malik RA, Potkar S, Wang Y-P. Systemic solutions for addressing non-communicable diseases in low- and middle-income countries [Internet]. Journal of Multidisciplinary Healthcare. 2020 ; 13 693-707.[citado 2024 nov. 15 ] Available from: https://doi.org/10.2147/JMDH.S252300
Vancouver
Ganju A, Goulart AC, Ray A, Majumdar A, Jeffers BW, Llamosa G, Cañizares H, Ramos-Cañizares IJ, Fadhil I, Subramaniam K, Lim L-L, El Bizri L, Ramesh M, Guilford M, Ali R, Devi RD, Malik RA, Potkar S, Wang Y-P. Systemic solutions for addressing non-communicable diseases in low- and middle-income countries [Internet]. Journal of Multidisciplinary Healthcare. 2020 ; 13 693-707.[citado 2024 nov. 15 ] Available from: https://doi.org/10.2147/JMDH.S252300
Trabalho de evento-resumo periodico
Use of triggers tool to detect adverse drug reactions in an adult emergency department at a Brazilian University Hospital (2019)
Gueiros, S; Takahashi, Patricia Sayuri Katayose; Rebello, F
Fonte: Drug Safety. Nome do evento: ISoP Annual Meeting "New Opportunities for New Generations". Unidade: HU
Assuntos: SERVIÇOS MÉDICOS DE EMERGÊNCIA, EVENTO ADVERSO A MEDICAMENTO, FARMACOVIGILÂNCIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GUEIROS, S e TAKAHASHI, Patricia Sayuri Katayose e REBELLO, F. Use of triggers tool to detect adverse drug reactions in an adult emergency department at a Brazilian University Hospital. Drug Safety. Auckland: Adis. Disponível em: https://doi.org/10.1007/s40264-019-00855-w. Acesso em: 15 nov. 2024. , 2019
APA
Gueiros, S., Takahashi, P. S. K., & Rebello, F. (2019). Use of triggers tool to detect adverse drug reactions in an adult emergency department at a Brazilian University Hospital. Drug Safety. Auckland: Adis. doi:10.1007/s40264-019-00855-w
NLM
Gueiros S, Takahashi PSK, Rebello F. Use of triggers tool to detect adverse drug reactions in an adult emergency department at a Brazilian University Hospital [Internet]. Drug Safety. 2019 ; 42( 10): 1249.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1007/s40264-019-00855-w
Vancouver
Gueiros S, Takahashi PSK, Rebello F. Use of triggers tool to detect adverse drug reactions in an adult emergency department at a Brazilian University Hospital [Internet]. Drug Safety. 2019 ; 42( 10): 1249.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1007/s40264-019-00855-w
Trabalho de evento-resumo periodico
The role of the clinical pharmacist in the detecting of suspected ADR in a secondary level hospital (2019)
Takahashi, Patricia Sayuri Katayose; Ricci, Monica Cristina Santos; Yanagita, Maria Luíza Bianco; Yamaguchi, Alice Misae; Paz, Karine Dal
Fonte: Drug Safety. Nome do evento: ISoP Annual Meeting "New Opportunities for New Generations". Unidade: HU
Assuntos: FARMÁCIA CLÍNICA, EVENTO ADVERSO A MEDICAMENTO, FARMACOVIGILÂNCIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
TAKAHASHI, Patricia Sayuri Katayose et al. The role of the clinical pharmacist in the detecting of suspected ADR in a secondary level hospital. Drug Safety. Auckland: Adis. Disponível em: https://doi.org/10.1007/s40264-019-00855-w. Acesso em: 15 nov. 2024. , 2019
APA
Takahashi, P. S. K., Ricci, M. C. S., Yanagita, M. L. B., Yamaguchi, A. M., & Paz, K. D. (2019). The role of the clinical pharmacist in the detecting of suspected ADR in a secondary level hospital. Drug Safety. Auckland: Adis. doi:10.1007/s40264-019-00855-w
NLM
Takahashi PSK, Ricci MCS, Yanagita MLB, Yamaguchi AM, Paz KD. The role of the clinical pharmacist in the detecting of suspected ADR in a secondary level hospital [Internet]. Drug Safety. 2019 ; 42( 10): 1212-1213.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1007/s40264-019-00855-w
Vancouver
Takahashi PSK, Ricci MCS, Yanagita MLB, Yamaguchi AM, Paz KD. The role of the clinical pharmacist in the detecting of suspected ADR in a secondary level hospital [Internet]. Drug Safety. 2019 ; 42( 10): 1212-1213.[citado 2024 nov. 15 ] Available from: https://doi.org/10.1007/s40264-019-00855-w
Artigo de periodico
Nasal high flow, but not supplemental O2, reduces peripheral vascular sympathetic activity during sleep in COPD patients (2018)
Fricke, K; Schneider, H; Biselli, Paolo José Cesare; Hansel, N N; Zhang, Z G; Sowho, M O; Grote, L
Fonte: International Journal of Chronic Obstructive Pulmonary Disease. Unidade: HU
Assuntos: DOENÇA PULMONAR OBSTRUTIVA CRÔNICA, SONO, OXIGENOTERAPIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FRICKE, K et al. Nasal high flow, but not supplemental O2, reduces peripheral vascular sympathetic activity during sleep in COPD patients. International Journal of Chronic Obstructive Pulmonary Disease, v. no 2018, p. 3635-3643, 2018Tradução . . Disponível em: https://doi.org/10.2147/COPD.S166093. Acesso em: 15 nov. 2024.
APA
Fricke, K., Schneider, H., Biselli, P. J. C., Hansel, N. N., Zhang, Z. G., Sowho, M. O., & Grote, L. (2018). Nasal high flow, but not supplemental O2, reduces peripheral vascular sympathetic activity during sleep in COPD patients. International Journal of Chronic Obstructive Pulmonary Disease, no 2018, 3635-3643. doi:10.2147/COPD.S166093
NLM
Fricke K, Schneider H, Biselli PJC, Hansel NN, Zhang ZG, Sowho MO, Grote L. Nasal high flow, but not supplemental O2, reduces peripheral vascular sympathetic activity during sleep in COPD patients [Internet]. International Journal of Chronic Obstructive Pulmonary Disease. 2018 ; no 2018 3635-3643.[citado 2024 nov. 15 ] Available from: https://doi.org/10.2147/COPD.S166093
Vancouver
Fricke K, Schneider H, Biselli PJC, Hansel NN, Zhang ZG, Sowho MO, Grote L. Nasal high flow, but not supplemental O2, reduces peripheral vascular sympathetic activity during sleep in COPD patients [Internet]. International Journal of Chronic Obstructive Pulmonary Disease. 2018 ; no 2018 3635-3643.[citado 2024 nov. 15 ] Available from: https://doi.org/10.2147/COPD.S166093
Trabalho de evento-resumo periodico
Triggers of active surveillance of adverse drug events in hospitalized newborns: a pilot study (2015)
Fabretti, Sandra de Carvalho; Lieber, Nicolina Silvana Romano; Brassica, Sandra Cristina; Ribeiro, Eliane ; Hernandez, C. Dagli
Fonte: Drug Safety. Nome do evento: International Society of Pharmacovigilance/ISoP. Unidades: HU, FCF
Assuntos: RECÉM-NASCIDO, MEDICAMENTO, FARMACOVIGILÂNCIA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FABRETTI, Sandra de Carvalho et al. Triggers of active surveillance of adverse drug events in hospitalized newborns: a pilot study. Drug Safety. Auckland: Hospital Universitário, Universidade de São Paulo. . Acesso em: 15 nov. 2024. , 2015
APA
Fabretti, S. de C., Lieber, N. S. R., Brassica, S. C., Ribeiro, E., & Hernandez, C. D. (2015). Triggers of active surveillance of adverse drug events in hospitalized newborns: a pilot study. Drug Safety. Auckland: Hospital Universitário, Universidade de São Paulo.
NLM
Fabretti S de C, Lieber NSR, Brassica SC, Ribeiro E, Hernandez CD. Triggers of active surveillance of adverse drug events in hospitalized newborns: a pilot study. Drug Safety. 2015 ; 38( 10): 847-1048.[citado 2024 nov. 15 ]
Vancouver
Fabretti S de C, Lieber NSR, Brassica SC, Ribeiro E, Hernandez CD. Triggers of active surveillance of adverse drug events in hospitalized newborns: a pilot study. Drug Safety. 2015 ; 38( 10): 847-1048.[citado 2024 nov. 15 ]
Artigo de periodico
S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis (2013)
Mazo, Daniel Ferraz de Campos; Oliveira, Marcelo G. de; Pereira, Isabel V. A.; Cogliati, Bruno ; Stefano, José Tadeu; Souza, Gabriela F. P. de; Rabelo, Fabíola; Lima, Fabiana R.; Alves, Venâncio Avancini Ferreira; Carrilho, Flair José; Oliveira, Cláudia Pinto Marques Souza de
Fonte: Drug Design, Development and Therapy. Unidades: FMVZ, HU, FM
Assuntos: CIRROSE HEPÁTICA (ETIOLOGIA), MODELOS ANIMAIS, HEPATOPATIAS, REAÇÃO EM CADEIA POR POLIMERASE, SEQUENCIAMENTO GENÉTICO, BIOQUÍMICA CELULAR
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MAZO, Daniel Ferraz de Campos et al. S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis. Drug Design, Development and Therapy, v. 7, p. 553-563, 2013Tradução . . Disponível em: https://doi.org/10.2147/DDDT.S43930. Acesso em: 15 nov. 2024.
APA
Mazo, D. F. de C., Oliveira, M. G. de, Pereira, I. V. A., Cogliati, B., Stefano, J. T., Souza, G. F. P. de, et al. (2013). S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis. Drug Design, Development and Therapy, 7, 553-563. doi:10.2147/DDDT.S43930
NLM
Mazo DF de C, Oliveira MG de, Pereira IVA, Cogliati B, Stefano JT, Souza GFP de, Rabelo F, Lima FR, Alves VAF, Carrilho FJ, Oliveira CPMS de. S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis [Internet]. Drug Design, Development and Therapy. 2013 ; 7 553-563.[citado 2024 nov. 15 ] Available from: https://doi.org/10.2147/DDDT.S43930
Vancouver
Mazo DF de C, Oliveira MG de, Pereira IVA, Cogliati B, Stefano JT, Souza GFP de, Rabelo F, Lima FR, Alves VAF, Carrilho FJ, Oliveira CPMS de. S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis [Internet]. Drug Design, Development and Therapy. 2013 ; 7 553-563.[citado 2024 nov. 15 ] Available from: https://doi.org/10.2147/DDDT.S43930

Unidades USP

ReP

Filtros

Departamento

Autores

Autores USP

Assuntos

Indexado em

Afiliação dos autores externos não normalizada

País das instituições de afiliação dos autores externos